Self-reported body silhouettes: a diagnostic instrument for anthropometric parameters.

OBJECTIVE: Routine body size measurement of anthropometric values requires professionals, standardized techniques, and calibrated tools. Therefore, there is a need for easier screening tools such as the self-reported body silhouette (Self-bosi). The aim of this study was to analyze the performance of Self-bosi as a proxy of anthropometric values. STUDY DESIGN: Prospective analytic study of the Health Workers Cohort Study. METHODS: Adult participants of the Health Workers Cohort Study were included. Then, through the calculation sensitivity and specificity of Self-bosi to detect abnormal waist circumference (WC) (≥90 cm for male and ≥80 cm for female participants), elevated body fat percentage (BF%) (≥25% for male and ≥35% for female participants), as well as overweight and obesity (≥25 kg/m2) and obesity (≥30 kg/m2). RESULTS: A total of 2471 male and 5940 female participants were analyzed. Overall, Self-bosi discriminate high WC values (area under the curve [AUC]; male participants: 0.80, female participants: 0.82); increased BF% (AUC: male participants: 0.78, female participants: 0.83); overweight and obesity (AUC: male participants: 0.81, female participants: 0.86); and obesity (AUC: male participants: 0.83, female participants: 0.89). CONCLUSION: Self-bosi is an accurate method to assess increased WC, BF%, obesity, and overweight-obesity in Mexican adults. Given its simplicity and low-cost of the self-reported body silhouette, it might be considered a useful anthropometric screening instrument in large scale epidemiological research.

Comparison of International Reference Values for Bone Speed of Sound in Pediatric Populations: Meta-analysis.

The aim of this study was to compare international reference values (RV) for tibial and radial speed of sound (SoS) assessed by quantitative ultrasound (QUS) in pediatric populations. These values were compared by age and country of origin in a systematic review with meta-analysis from studies published on QUS (Sunlight Omnisense). A search was carried out in electronic databases. Nine studies with 6963 patients were included in the meta-analysis. For the newborn populations, 3 studies (from Italy, Portugal, and Israel) were used. These studies included subjects with 27-42 wk gestational age. The mean difference (Portugal-Israel) was found to be 23.62 m/s [95% confidence interval [CI] 6.29, 40.95]. Additionally, no difference was found between Italy-Portugal (p = 0.69), or Italy-Israel (p = 0.28). In pediatric populations, we compared 8 studies from Canada, Mexico, Israel, Greece, Portugal, and Turkey. No significant differences found for SoS RV between Israel-Turkey, Israel-Greece, or Israel-Canada (p > 0.05). Significant differences were found in Mexico-Israel -105.29 m/s (95% CI -140.05, -70.54) (p < 0.001); Mexico-Portugal -115.14 m/s (95% CI -164.86, -65.42) (p < 0.001); Mexico-Greece: -239.14 m/s (95% CI -267.67, -210.62) (p < 0.001); Mexico-Turkey: -115.14 m/s (95% CI -164.86, -65.42) (p < 0.001); Mexico-Canada: -113.51 m/s (95% CI -140.25, -86.77) (p < 0.001).This study demonstrates that there are differences in SoS-RV obtained by tibial and radial QUS in pediatric populations between Mexico and other countries (Israel, Portugal, Greece, Turkey, and Canada).

Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis.

OBJECTIVE: Our review analyses the studies that have specifically compared the association iDPP4/metformin with glimepiride/metformin, both in second line pharmacotherapy of type 2 diabetes mellitus (DM2). METHODS: Systematic literature review with a meta-analysis of clinical trials comparing glimepiride with any iDPP4, both used together with metformin as a second line treatment of DM2. The effectiveness variables used were as follows: %HbA1c variation, fasting plasma glucose variation, patients achieving the therapeutic objective of HbA1c <7%, treatment dropouts due to lack of effectiveness and rescue treatments needed. The safety variables included were as follows: weight variation at the end of treatment; presentation of any type of adverse event; presentation of serious adverse events; patients who experienced any type of hypoglycaemia; patients who experienced severe hypoglycaemia; treatments suspended due to adverse effects; and deaths for any reason. RESULTS: Four studies met the inclusion criteria. The group treated with glimepiride showed better results in all effectiveness variables. Regarding safety variables, the main differences observed were in the greater number of cases with hypoglycaemia in the group treated with glimepiride, and the serious adverse events or treatment discontinuations due to these which occurred in slightly over 2% more cases in this group compared to the iDPP4 group. The remaining adverse events, including mortality, did not show any differences between both groups. The variation in the weight difference between groups (2.1 kg) is not considered clinically relevant. CONCLUSIONS: A greater effectiveness is seen in the glimepiride/metformin association, which should not be diminished by slight differences in adverse effects, with absence of severe hypoglycaemia in over 98% of patients under treatment. The association of glimepiride/metformin, both due to cost as well as effectiveness and safety, may be the preferential treatment for most DM2 patients, and it offers a potential advantage in refractory hyperglycemic populations, tolerant to treatment.

The importance of lactose intolerance in individuals with gastrointestinal symptoms. / Importancia de la intolerancia a la lactosa en individuos con síntomas gastrointestinales.

Lactose intolerance is a condition with an elevated prevalence worldwide, especially in Latin American, Asian, and African countries. The aim of the present narrative review was to highlight the importance of accurately diagnosing lactose intolerance to prevent self-diagnosis that results in the unnecessary elimination of milk and dairy products from the diet and the consequent deprivation of nutrients that could be essential at certain stages of life. The pathophysiologic mechanism of deficient lactose absorption in the intestine can be primary, secondary to other enteropathies, or coexistent with other intestinal diseases with similar symptoms, such as irritable bowel syndrome, bacterial overgrowth syndrome, or celiac disease, causing confusion in relation to diagnosis and treatment. Lactose intolerance consists of a set of symptoms attributed to the consumption of milk and dairy products that are assumed to be due to deficient digestion of that disaccharide. A wide range of tests have been validated to detect deficient digestion that include blood tests, genetic mutation analyses, breath tests, and recently, a urine test, all of which are described in the present article. Nevertheless, there are few validated questionnaires for symptom evaluation and measurement, partly due to the heterogeneity of concepts and the subjectivity of each of the symptoms.

[Comment to the article «Frecuency of diagnosis of bone lesions in cases of anterior glenohumeral dislocation¼]. / Carta al editor sobre el artículo «Frecuencia de diagnóstico de lesiones óseas en luxación glenohumeral anterior¼.

No Abstract available.

[Utility of the clinical risk index for babies (CRIB) as a predictor of hospital death and intraventricular hemorrhage in very low birth weight and extremely low birth weight neonates]. / Utilidad del CRIB para predecir la muerte hospitalaria y la hemorragia intraventricular en los prematuros de muy bajo peso y extremado bajo peso al nacer.

OBJECTIVE: To assess the utility of the CRIB score as a predictor of hospital death and intraventricular hemorrhage (IVH) in very low birth weight (VLBW) and extremely low birth weight (ELBW) neonates. METHOD: A prospective cohort of VLBW neonates admitted to the neonatal intensive care unit from January 2002 to December 2004 was studied. The data was assessed following the protocol of the SEN 1500 multicenter study. This protocol included assessment of the CRIB score in the first 12 hours of life. Data for the entire group, as well as for two subgroups divided according to birth weight (BW) - VLBW neonates (between 1000 and 1500 g) and ELBW neonates (below 1,000 g) - were evaluated. The area under the receiver operating characteristic curve (Az) was calculated to assess the utility of CRIB score, BW and gestational age (GA). Two multivariate models were used. RESULTS: The cohort consisted of 163 patients. The mean (+/-SD) birthweight was 1.114 (+/-270) g and gestational age (+/-SD) was 29 (+/-3) weeks. The Az for hospital death was 0.757 for the CRIB, 0.758 for BW and 0.703 for GA. The Az for IVH was 0.66 for the CRIB, 0.62 for BW and 0.64 for GA. In the multivariate models for hospital death and IVH, the CRIB was the best predictor. The Az of the CRIB for hospital death was 0.77 for VLBW neonates (p < 0.001) and 0.63 for ELBW neonates (p = 0.82). CONCLUSIONS: The predictive utility of the CRIB for hospital death and IVH is similar to that of BW. In the stratification by groups of weight, we found that the CRIB was the best predictor of hospital death in the group weighing > 1,000 g but was no better than chance in the group weighing < 1,000 g.

Post-Renal Transplantation Bone Health in Children Evaluated by Means of Quantitative Ultrasound and Densitometry.

BACKGROUND: Patients with end-stage renal disease develop bone mineral disease, which is not always resolved after a successful renal transplantation; moreover, some of the immunosuppressants used to prevent graft rejection may affect bone health. The aim of this study was to evaluate bone health in post-renal transplantation children with the use of quantitative ultrasound (QUS) and dual-energy X-ray absorptiometry (DXA). METHODS: A descriptive study was performed in children >3 months after renal transplantation and with stable function of graft. Radial QUS and DXA (lumbar spine and total body less head (TBLH) were performed on the same day. RESULTS: A total of 35 patients were included. Mean age was 13.9 ± 3.9 years. Ten subjects had total bone density score <2 (28.5%), 4 a lumbar spine (L1-L4) Z-score of <2 (11.4%) as well as TBLH <2, and 6 subjects had a radial QUS Z-score of <2 (17.1%), and only 2 of them had concomitant Z-score <2 with the use of DXA. There was a positive non-significant correlation between TBLH and radial QUS Z-scores (Pearson r = 0.317; P = .016) and a positive significant correlation of DXA lumbar spine and radial QUS Z-scores (Pearson r = 0.452; P = .014). CONCLUSIONS: Despite a good correlation between TBLH and QUS Z-scores, there are subjects that can be considered normal by QUS and have osteopenia by TBLH DXA and vice versa; this could be due to the different bone areas evaluated.

Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up.

OBJECTIVE: To determine the rate and factors associated with ankylosing spondylitis in a cohort of patients with undifferentiated spondyloarthritides (SpA). METHODS: 62 consecutive patients with undifferentiated SpA seen between 1998 and 1999 underwent clinical and imaging evaluations throughout follow up. The main outcome measure was a diagnosis of ankylosing spondylitis. RESULTS: 50 patients with peripheral arthritis (n = 35) and inflammatory back pain (n = 24) (26 male; mean (SD) age at onset, 20.4 (8.8) years; disease duration 5.4 (5.7) years) were followed up for 3-5 years. At baseline, >90% of patients had axial and peripheral disease, while 38% had radiographic sacroiliitis below the cut off level for a diagnosis of ankylosing spondylitis (BASDAI 3.9, BASFI 2.9). At the most recent evaluation, 21 patients (42%) had ankylosing spondylitis. Two factors were associated with a diagnosis of ankylosing spondylitis in multivariate analysis: radiographic sacroiliitis grade <2 bilateral, or grade <3 unilateral (odds ratio (OR) = 11.18 (95% confidence interval, 2.59 to 48.16), p = 0.001), particularly grade 1 bilateral (OR = 12.58 (1.33 to 119.09), p = 0.027), and previous uveitis (OR = 19.25 (1.72 to 214.39), p = 0.001). Acute phase reactant levels, juvenile onset, and HLA-B27 showed a trend to linkage with ankylosing spondylitis (NS). CONCLUSIONS: Low grade radiographic sacroiliitis is a prognostic factor for ankylosing spondylitis in patients originally classified as having undifferentiated SpA. Low grade radiographic sacroiliitis should be regarded as indicative of early ankylosing spondylitis in patients with undifferentiated SpA.

¿Es el CRIB un buen predictor de hemorragia intraventricular?. Réplica / Is the CRIB a good predictor of intraventricular hemorrhage?. Reply

No disponible

Utilidad del CRIB para predecir la muerte hospitalaria y la hemorragia intraventricular en los prematuros de muy bajo peso y extremado bajo peso al nacer / Utility of the clinical risk index for babies (CRIB) as a predictor of hospital death and intraventricular hemorrhage in very low birth weight and extremely low birth weight neonates

Objetivo Evaluar la utilidad del Clinical Risk Index for Babies (CRIB) para predecir la muerte hospitalaria y la hemorragia intraventricular (HIV) en pacientes recién nacidos prematuros de muy bajo peso (RNMBP) y de peso extremadamente bajo al nacer (RNEBP). Método Se siguió de forma prospectiva una cohorte de recién nacidos con peso inferior a 1.500 g ingresados en la unidad de cuidados intensivos neonatales (UCIN), desde enero de 2002 a diciembre de 2004. Se registraron datos de morbimortalidad del estudio multicéntrico SEN-1500, incluida la valoración del CRIB a las 12 h de vida. Se evaluaron los datos globales así como en dos subgrupos según peso: muy bajo peso (entre 1.000 y 1.500 g) y peso extremadamente bajo (< 1.000 g). Se realizaron curvas ROC para estimar el poder de predicción mediante el área bajo la curva (Az) y se procesaron modelos multivariantes. Resultados Se registraron los datos de 163 pacientes. La media de peso al nacer (+DE) fue de 1.114 g (±270) y de edad gestacional (+DE) fue de 29 semanas (±3). El Az del CRIB para la muerte intrahospitalaria fue 0,757, del peso al nacer 0,758 y de la edad gestacional 0,703. El Az del índice CRIB para la HIV fue 0,66, del peso 0,62 y de edad gestacional 0,64. En los dos modelos multivariantes para mortalidad y HIV, el CRIB fue el mejor predictor. En el grupo de RNMBP el Az del CRIB para la muerte hospitalaria fue 0,77 (p < 0,001), siendo 0,63 en el grupo de RNEBP (p = 0,82). Conclusiones La utilidad del CRIB en los recién nacidos menores de 1.500 g para predecir muerte hospitalaria y HIV es similar a la del peso. Al estratificar por grupos de peso, encontramos que en los pacientes mayores de 1.000 g, el CRIB fue el mejor predictor de muerte hospitalaria, mientras que en los menores de 1.000 g el CRIB no fue mejor que el azar

Objective To assess the utility of the CRIB score as a predictor of hospital death and intraventricular hemorrhage (IVH) in very low birth weight (VLBW) and extremely low birth weight (ELBW) neonates. Method A prospective cohort of VLBW neonates admitted to the neonatal intensive care unit from January 2002 to December 2004 was studied. The data was assessed following the protocol of the SEN 1500 multicenter study. This protocol included assessment of the CRIB score in the first 12 hours of life. Data for the entire group, as well as for two subgroups divided according to birth weight (BW) ­ VLBW neonates (between 1000 and 1500 g) and ELBW neonates (below 1,000 g) ­ were evaluated. The area under the receiver operating characteristic curve (Az) was calculated to assess the utility of CRIB score, BW and gestational age (GA). Two multivariate models were used. Results The cohort consisted of 163 patients. The mean (±SD) birthweight was 1.114 (±270) g and gestational age (±SD) was 29 (±3) weeks. The Az for hospital death was 0.757 for the CRIB, 0.758 for BW and 0.703 for GA. The Az for IVH was 0.66 for the CRIB, 0.62 for BW and 0.64 for GA. In the multivariate models for hospital death and IVH, the CRIB was the best predictor. The Az of the CRIB for hospital death was 0.77 for VLBW neonates (p 1,000 g but was no better than chance in the group weighing < 1,000 g